期刊文献+

酶增强免疫分析法监测他克莫司血药浓度质控评估 被引量:3

Assessment the quality control of the blood concentrations of Tacrolimus monitored by EMIT
下载PDF
导出
摘要 目的:探讨用酶增强免疫分析法监测他克莫司血药浓度的质量,确定适合于本实验室的他克莫司药物监测质控规则。方法:以标准质控为样本,分析用酶增强免疫法测定他克莫司血药浓度方法的稳定性和准确性,并对我院2009年的质控结果进行评价、分析,建立新的质控规则。结果:在本实验室条件下,他克莫司测定值为20℃、21℃、23℃、24℃时,与22℃时测定值比较,差异均有统计学意义(P<0.05);他克莫司高中低三个浓度的RSD为3.4%~10.1%,回收率为96.1%~105.4%,均符合《中国药典》对生物样品检测规定;本实验室新的质控规则为12s/13s/22s/41s。结论:用酶增强免疫分析法检测他克莫司血药浓度的方法稳定性和准确性较好,可以在临床中推广应用,但合理质控规则的建立是此方法实施的保障。 Objective: To explore the measurement quality that the blood concentrations of Tacrolimus by enzyme-multi- plied immunoassay technique(EMIT)and establish quality control rule of blood concentrations of Tacrolimus which suit for our laboratory. Methods: The stabilization and precision of the method were analysis used standard as a sample copy. We analyzed and evaluated the quality control results of 2009 in our laboratory. Results: There were a significant difference between the blood concentrations of tacrolimus at 21℃, 23℃, 24℃and that at 22℃(P〈0.05); the RSD of tacrolimus was from 3.4% to 10.1%, the recovery was from 96.1% to 105.4%, they all met the requirements of pharmacopoeia, and we established the new quality control results. Conclusion: This method have a certain consistency and a high precision and can apply to the clinical treatment, but must established a reasonable quality control rule.
作者 徐雨佳
出处 《中国医药导报》 CAS 2011年第7期52-54,共3页 China Medical Herald
关键词 酶增强免疫法 他克莫司 血药监测 质控规则 Enzyme-multiplied immunoassay technique Tacrolimus Blood concentration monitoring Quality control13dles
  • 相关文献

参考文献8

二级参考文献69

共引文献88

同被引文献37

  • 1邹远高,白杨娟,王兰兰,唐江涛.酶放大免疫分析法测定环孢霉素和普乐可复的血药浓度[J].华西药学杂志,2010,25(5):582-584. 被引量:5
  • 2陈新谦,金有豫,汤光.新编药物学[M].北京:人民卫生出版社,2011:609-621.
  • 3陈泰昌.搞好血药浓度监测的措施[D].首届全国药学服务与研究学术会议论文集,2004:114-116.
  • 4Mtndez A, Berastegui C, L6pez-Meseguer M,et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once- daily in stable lung transplantation [ J ]. Transplantation, 2014,97 (3) :358-362.
  • 5Zheng S, Easterling TR, Umans JG, et al. Pharmacokinetics of tacrolimus during pregnancy [ J ]. Ther Drug Monit, 2012,34 ( 6 ) : 660-670.
  • 6Borgrnan MP, Hiemer MF, Molinelli AR, et al. Improved sensitivity for methotrexate analysis using enzyme multiplied y technique on the Siemens Viva-E instrument [ J ]. Ther Drug Monit ,2012,34 ( 2 ) : 193-197.
  • 7Beck O, Ransberg L, A1-Saffar Y, et al. Detectability of new psychoactive substances, 'legal highs', in CEDIA, EMIT, and KIMS immunochemical screening assays for drugs of abuse [ J ]. Drug Test Anal ,2014,6(5 ) :492-499.
  • 8Konishi H, Iga I, Nagai K. Underestimation of rat serum vancom- vein concentrations measured by an enzyme-multiplied immuno- assay technique and the strategy for its avoidance [ J ]. Drug Test Anal ,2014,6(4) :350-356.
  • 9Min SI, Ha J, Kim YS, et al. Therapeutic equivalence and pharma- cokinetics of generic tacrolimus formulation in de novo kidney transplant patients [ J ]. Nephrol Dial Transplant, 2013,28 ( 12 ) : 3110-3119.
  • 10Frassetto LA, Tan-Tam CC, Barin B, et al. Best single time point correlations with AUC for cyelosporine and tacrolimus in HIV- infected kidney and liver transplant recipients [ J ]. Transplantation, 2014,97 ( 6 ) :702 -707.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部